SVB, the parent of the Silicon Valley Bank, is projecting healthcare investment and financing to fall by $15 billion in 2023, based on how recently firms raised new funds and the pace of investment to be slower than 2021, per Becker’s.
In the medtech market, SVB predicts that late-stage investment will continue to slow and major firms will push back going public until at least late 2023 because of market pressures, according to a Jan. 6 SVB news release.
“Looking ahead to 2023, while there is still uncertainty in the private investment landscape, the strongest companies will get funded,” SVB Managing Director Jonathan Norris said.
